282 related articles for article (PubMed ID: 27854302)
41. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype.
Chen YC; Chu CY; Hsiao CH
J Eur Acad Dermatol Venereol; 2009 Jun; 23(6):702-3. PubMed ID: 18785891
[No Abstract] [Full Text] [Related]
42. An update on HLA alleles associated with adverse drug reactions.
Fricke-Galindo I; LLerena A; López-López M
Drug Metab Pers Ther; 2017 May; 32(2):73-87. PubMed ID: 28315856
[TBL] [Abstract][Full Text] [Related]
43. New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity.
Michels AW; Ostrov DA
J Allergy Clin Immunol; 2015 Aug; 136(2):252-7. PubMed ID: 26254052
[TBL] [Abstract][Full Text] [Related]
44. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI
Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
[TBL] [Abstract][Full Text] [Related]
45. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
46. HLA-B∗ 1502 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population.
Aggarwal R; Sharma M; Modi M; Garg VK; Salaria M
Hum Immunol; 2014 Nov; 75(11):1120-2. PubMed ID: 25305458
[TBL] [Abstract][Full Text] [Related]
47. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
Hung SI; Chung WH; Liou LB; Chu CC; Lin M; Huang HP; Lin YL; Lan JL; Yang LC; Hong HS; Chen MJ; Lai PC; Wu MS; Chu CY; Wang KH; Chen CH; Fann CS; Wu JY; Chen YT
Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4134-9. PubMed ID: 15743917
[TBL] [Abstract][Full Text] [Related]
48. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity.
Pirmohamed M; Ostrov DA; Park BK
J Allergy Clin Immunol; 2015 Aug; 136(2):236-44. PubMed ID: 26254050
[TBL] [Abstract][Full Text] [Related]
49. Pharmacogenomics of adverse drug reactions: implementing personalized medicine.
Wei CY; Lee MT; Chen YT
Hum Mol Genet; 2012 Oct; 21(R1):R58-65. PubMed ID: 22907657
[TBL] [Abstract][Full Text] [Related]
50. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report.
Lin LC; Lai PC; Yang SF; Yang RC
Kaohsiung J Med Sci; 2009 Feb; 25(2):82-6. PubMed ID: 19321411
[TBL] [Abstract][Full Text] [Related]
51. Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation.
Sukasem C; Puangpetch A; Medhasi S; Tassaneeyakul W
Asian Pac J Allergy Immunol; 2014 Jun; 32(2):111-23. PubMed ID: 25003724
[TBL] [Abstract][Full Text] [Related]
52. Role of dermatology in pharmacogenomics: drug-induced skin injury.
Borroni RG
Pharmacogenomics; 2015; 16(4):401-12. PubMed ID: 25823788
[TBL] [Abstract][Full Text] [Related]
53. T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction.
Ko TM; Chen YT
Expert Rev Clin Immunol; 2012 Jul; 8(5):467-77. PubMed ID: 22882221
[TBL] [Abstract][Full Text] [Related]
54. Rapidly Progressing Severe Cutaneous Adverse Reaction With Acute Kidney Injury After Drug Exposure: An Uncommon Presentation.
Rodgers BK; Kumar AB
Am J Ther; 2016; 23(3):e916-9. PubMed ID: 24832386
[TBL] [Abstract][Full Text] [Related]
55. Recent advances in the understanding of severe cutaneous adverse reactions.
Adler NR; Aung AK; Ergen EN; Trubiano J; Goh MSY; Phillips EJ
Br J Dermatol; 2017 Nov; 177(5):1234-1247. PubMed ID: 28256714
[TBL] [Abstract][Full Text] [Related]
56. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
57. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.
Ingelman-Sundberg M
N Engl J Med; 2008 Feb; 358(6):637-9. PubMed ID: 18256400
[No Abstract] [Full Text] [Related]
58. Drug eruptions induced by allopurinol associated with HLA-B*5801.
Zeng M; Zhang M; Liu F; Yan W; Kong Q; Sang H
Indian J Dermatol Venereol Leprol; 2015; 81(1):43-5. PubMed ID: 25566896
[TBL] [Abstract][Full Text] [Related]
59. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Harr T; French LE
Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
[TBL] [Abstract][Full Text] [Related]
60. Pharmacogenetics of allopurinol--making an old drug safer.
Lam MP; Yeung CK; Cheung BM
J Clin Pharmacol; 2013 Jul; 53(7):675-9. PubMed ID: 23381951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]